Physician profile
Luis E Valle
NPI 1497214431
$4,945.07
in general payments reported to CMS, 2019-2025
17 companies · $1,329 in 2025
The $1,329 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.93 · 2022: $458 · 2023: $1,009 · 2024: $2,133 · 2025: $1,329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,471.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,471.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $978.86 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $877.31 | 2022-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $812.93 | 2022-2025 | Ubrelvy, Qulipta, Linzess |
| Amgen INC. | $527.10 | 2022-2025 | Otezla, Krystexxa, Repatha |
| Phathom Pharmaceuticals, INC. | $364.84 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $359.55 | 2024-2025 | |
| Lilly USA, LLC | $215.12 | 2024-2025 | Mounjaro, Zepbound, Kisunla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $205.30 | 2022-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $144.33 | 2023-2024 | Camzyos, Eliquis |
| Xeris Pharmaceuticals, INC. | $112.81 | 2024-2025 | Gvoke Hypopen |
| Glaxosmithkline, LLC. | $83.85 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.31 | 2023-2024 | Xifaxan, Trulance |
| Exact Sciences Corporation | $61.29 | 2024-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $49.77 | 2025 | Rexulti |
| Aimmune Therapeutics, INC. | $28.44 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $24.33 | 2025 | Gemtesa |
| Takeda Pharmaceuticals U.S.A., INC. | $15.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Valle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.